

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Mortality risk in COVID-19 patients, early treatment with pegylated interferon lambda, ATAGI 2023 booster advice

Peer reviewed journals featured:

- A systematic review on antimicrobial resistance in COVID-19 patients [here](#)
- A meta- and network analysis on the risk of mortality in COVID-19 patients [here](#)
- Randomised clinical trials of:
 - Methylprednisolone vs intravenous immunoglobulins in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 [here](#)
 - Early treatment with pegylated interferon lambda for COVID-19 [here](#)
- A narrative review on postural orthostatic tachycardia syndrome in long COVID [here](#)
- Observational studies on:
 - Adherence to healthy lifestyle prior to infection and risk of post-COVID-19 condition [here](#)
 - CoronaVac and Comirnaty (Pfizer) vaccine effectiveness against severe outcomes over time in patients with Omicron [here](#)
 - Guillain-Barré Syndrome after COVID-19 vaccination in the US [here](#)
 - Outcomes following delivery in pregnant and postpartum patients with severe COVID-19 pneumonitis admitted to ICU in Israel [here](#) and associated commentary [here](#)
 - The risk of SARS-CoV-2 infection and hospitalisation in vaccinated and previously infected people in Italy [here](#)
 - ED presentations during the COVID-19 pandemic in Queensland [here](#)
 - Factors associated with hospitalisations and deaths of aged care residents with COVID-19 during the Omicron (BA.1) wave in Queensland [here](#)
- Commentary on bivalent COVID-19 vaccines [here](#)

Letters and correspondence discussed:

- Antibody response to Omicron BA.4–BA.5 bivalent booster [here](#)
- China needs a scientific long COVID recovery-support platform [here](#)
- Ignoring SARS-CoV-2 testing performance during COVID-19 [here](#)
- Transmissibility, infectivity, and immune resistance of the Omicron XBB.1.5 variant [here](#) and [here](#)
- Incidence of chronic spontaneous urticaria after COVID-19 vaccine booster in Switzerland [here](#)
- Immunogenicity of BA.5 bivalent mRNA vaccine boosters [here](#)

Pre-peer review articles featured:

- Long-term symptomology of post-COVID-19 olfactory and gustatory dysfunction [here](#)
- Autoantigen profiling in fully recovered and long COVID patients [here](#)
- Neutralisation of BQ.1.1 and XBB.1.5 by breakthrough infection sera from previous and current waves [here](#)
- Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1 [here](#)
- Immunogenicity of the BA.1 and BA.4/5 bivalent boosts [here](#)
- Severe cerebral venous sinus thrombosis in post-vaccination breakthrough COVID-19 infection [here](#)
- Antibody responses post-vaccination and severe COVID-19 outcomes in Scotland [here](#)
- Associations of COVID-19 symptoms with Omicron BA.2 and BA.5 subvariants, host status, and clinical outcomes in Sapporo, Japan [here](#)
- Bivalent mRNA booster vaccines in patients with haematological neoplasms [here](#)

Guidance and reports

- The World Health Organisation published its weekly COVID-19 epidemiological report [here](#)
- The Australian Technical Advisory Group on Immunisation (ATAGI) recommendations on:
 - COVID-19 boosters in 2023 [here](#)
 - Use of the Pfizer bivalent (Original/Omicron BA.4/5) COVID-19 vaccine [here](#)
- A CDC summary of the WHO report on COVID-19 mortality and vaccinating older adults [here](#)
- Convalescent plasma to treat immunocompromised COVID-19 patients [here](#)

News and blogs

- Newly discovered host-cell factor could be a COVID-19 treatment target [here](#)
- Hybrid immunity more protective than prior SARS-CoV-2 infection alone [here](#)
- How quickly does COVID-19 immunity fade? [here](#)
- COVID-19 drug (molnupiravir) drives viral mutations and some want to halt its use [here](#)
- Reduction in payments for NHS staff with long term symptoms [here](#)
- FDA removes US authorisation for antibody drug Evusheld [here](#)
- The US will end public health emergency on 11 May, says Biden [here](#)
- TGA confirms the performance of Australian approved Rapid Antigen Tests with COVID-19 variants [here](#)

[Click here](#) to subscribe, or unsubscribe from, the evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, and [post-acute sequelae of COVID-19 \(long COVID\)](#).



Health

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.